Loading…
Operator of micro-hospitals and freestanding emergency rooms providing emergency and outpatient care in local communities.
Operator of micro-hospitals and freestanding emergency rooms providing emergency and outpatient care in local communities.
Bills each patient's insurer for emergency visits, and much of its income comes from out-of-network claims, which pay more than contracted rates but are negotiated or disputed afterwards, so collections vary. Facilities are concentrated in Texas. It became public through a 2022 merger with Clinigence Holdings.
Moat: narrow (regulatory licence, distribution). State-licensed micro-hospital model provides emergency access in underserved areas, though model draws billing scrutiny.
Headquarters: Houston, Texas · Founded: 2011 · Employees: 944
Size Nutex Health (NUTX) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.24B, the 2120th largest of 3,117 United States companies the cockpit tracks. Shares closed at $180.56 on 6 Nov 2026.
Performance Over six months the shares gained 32.1%, against +20.6% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 6.9% over the last twelve months (peer median +6.8%); the operating margin is 43.0% (peer median 5.0%).
Valuation It trades at 7.2× forward earnings against a peer median of 25.1× (cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -19% a year for seven years (Req g). Recent delivered growth is +253%, so the hurdle is -273 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 30.3 points above its cost of capital (7.6% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $847M | $875M | $480M | $248M | $219M |
| Revenue growth | — | +82% | +94% | +13% | — |
| Gross profit | $434M | $444M | $196M | $34.8M | $13.5M |
| EBITDA | $385M | $296M | $157M | $16.3M | $8.62M |
| Net income | $180M | $70.8M | $52.1M | -$45.8M | -$425M |
| Free cash flow | $274M | $246M | $20.8M | -$8.24M | $36.0M |
| Capital expenditure | $5.45M | $2.53M | $2.30M | $9.50M | $14.6M |
| Total debt | $347M | $351M | $340M | $276M | $267M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Nutex Health NUTX | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% |
| HCA Healthcare HCA | $103B | +14% | +6% | 15% | 16.2× | 3.3% |
| Community Health Systems CYH | $312M | -21% | -8% | 7% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NUTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.9% | +4.8% | lowest of 21 |
| 6-month return | +32.1% | +20.6% | 5th highest of 21 |
| Distance from 52-week high | -20.2% | -16.0% | 8th lowest of 21 |
| Revenue growth (TTM) | +6.9% | +6.8% | 11th highest of 21 |
| Operating margin | 43.0% | 5.0% | highest of 21 |
| Forward P/E | 7.2× | 25.1× | cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -19.5% | 14.8% | least demanding of 17 |
| Growth delivered (Del g) | +253.5% | +9.7% | highest of 17 |
| Hurdle (Req g minus delivered) | -272.9 pp | +1.0 pp | least demanding of 17 |
| ROIC minus cost of capital | +30.3 pp | -3.7 pp | highest of 20 |
| EV / EBITDA | 3.9× | 11.6× | cheapest of 17 |
| Net debt / EBITDA | 0.4× | 1.3× | 6th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |